Evidence map›Paper›PMID 34067361›Full record

ArticleViruses2021

Evaluation of Dried Blood Spot Testing for SARS-CoV-2 Serology Using a Quantitative Commercial Assay.

Davor Brinc, Mia J Biondi, Daniel Li, Heng Sun, Camelia Capraru, David Smookler, Muhammad Atif Zahoor, Julia Casey, Vathany Kulasingam, Jordan J Feld

Open access · goldAbstract readEvaluation Study
In one paragraph

Article in Viruses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Diagnostic performance of the SARS-CoV-2 S1RBD IgG ELISA (ImmunoDiagnostics) for the quantitative detection of SARS-CoV-2 antibodies on dried blood spots.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2022
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Davor BrincDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada.
Mia J BiondiViral Hepatitis Care Network (VIRCAN) Study Group, Toronto Centre for Liver Disease, Toronto, ON M5G 2C, Canada.ORCID 0000-0002-1409-9908
Daniel LiInstitute of Medical Science, University of Toronto, Toronto, ON M5S 1A8, Canada.ORCID 0000-0003-0193-9709
Heng SunDepartment of Clinical Biochemistry, University Health Network, Toronto, ON M5G 2C4, Canada.
Camelia CapraruViral Hepatitis Care Network (VIRCAN) Study Group, Toronto Centre for Liver Disease, Toronto, ON M5G 2C, Canada.
David SmooklerViral Hepatitis Care Network (VIRCAN) Study Group, Toronto Centre for Liver Disease, Toronto, ON M5G 2C, Canada.
Muhammad Atif ZahoorViral Hepatitis Care Network (VIRCAN) Study Group, Toronto Centre for Liver Disease, Toronto, ON M5G 2C, Canada.ORCID 0000-0003-2302-3689
Julia CaseyViral Hepatitis Care Network (VIRCAN) Study Group, Toronto Centre for Liver Disease, Toronto, ON M5G 2C, Canada.
Vathany KulasingamDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada.
Jordan J FeldViral Hepatitis Care Network (VIRCAN) Study Group, Toronto Centre for Liver Disease, Toronto, ON M5G 2C, Canada.
Toronto Liver Centre · CAUniversity Health Network · CAUniversity of Toronto · CA

Funding

Ontario First COVID-19 Rapid Research Fund N/AToronto COVID-19 Action Initiative N/AToronto General and Western Hospital Foundation N/AUniversity of Toronto N/A
6 · The paper itself

Abstract

Dried blood spots (DBS) are commonly used for serologic testing for viruses and provide an alternative collection method when phlebotomy and/or conventional laboratory testing are not readily available. DBS collection could be used to facilitate widespread testing for SARS-CoV-2 antibodies to document past infection, vaccination, and potentially immunity. We investigated the characteristics of Roche's Anti-SARS-CoV-2 (S) assay, a quantitative commercial assay for antibodies against the spike glycoprotein. Antibody levels were reduced relative to plasma following elution from DBS. Quantitative results from DBS samples were highly correlated with values from plasma (

Indexed as

COVID-19 Serological TestingDried Blood Spot TestingAntibodies, ViralCOVID-19HumansReproducibility of ResultsSARS-CoV-2Sensitivity and SpecificitySpike Glycoprotein, CoronavirusAntibodies, ViralSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2antibodyCOVID-19dried blood spotSARS-CoV-2serology

Identifiers

PMID34067361
PMCPMC8224688
OpenAlexW3164101420

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.